Inventor

VAN DER BRUGGEN PIERRE

BE63 patents

⚠️ This page may combine multiple inventors who share the name “VAN DER BRUGGEN PIERRE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

VAN DER BRUGGEN PIERRE

LUDWIG INST CANCER RES

MAGE-A4 antigenic peptides and uses thereof

Isolated nonapeptides derived from MAGE genes and uses thereof

Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof

Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells

Mage-3 peptides presented by HLA class II molecules

Isolated nucleic acid molecules which encode MAGE derived nonapeptides

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Mage-3 peptides presented by HLA class II molecules

Method for treating cancer by administering MAGE-derived peptides

Tumor rejection antigen precursors, tumor rejection antigens and uses thereof

MAGE-3 peptides presented by HLA class II molecules

Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof

Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Tumor antigens and CTL clones isolated by a novel procedure

Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

MAGE-A3 peptides presented by HLA class II molecules

Mage-A3 peptides presented by HLA class molecules

Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 gene products

MAGE peptides presented by HLA class II molecules

MAGE-3 peptides presented by HLA class II molecules

Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof

Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1

Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules

Method for stimulating CTLs with peptides

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Isolated nonapeptides presented by HLA molecules, and uses thereof

Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3

Tumor antigens and CTL clones isolated by a novel procedure

Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof

Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3

Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof

Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof

MAGE-A1 peptides presented by HLA class II molecules

Isolated nucleic acid molecules which encode GAGE genes and uses thereof

Isolated peptides which complex with HLA-Cw16 and uses thereof

Isolated peptides which complex with HLA-Cw*16 molecules, and uses thereof

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereof

Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof

Cytolytic T cell lines which bind to complexes of tumor rejection antigens and HLA-B44 molecules

Tumor antigens and CTL clones isolated by a novel procedure

Isolated peptides which bind to HLA-B18 molecules and uses thereof

Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules

UNIV LEIDEN

Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof

UNIV MAINZ JOHANNES GUTENBERG

Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients

DEMOTTE NATHALIE

Method for modulating activity of T lymphocytes